Exact Mass: 957.5018525999999
Exact Mass Matches: 957.5018525999999
Found 28 metabolites which its exact mass value is equals to given mass value 957.5018525999999,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
PG(20:2(11Z,14Z)/LTE4)
PG(20:2(11Z,14Z)/LTE4) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(20:2(11Z,14Z)/LTE4), in particular, consists of one chain of one 11Z,14Z-eicosadienoyl at the C-1 position and one chain of Leukotriene E4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).
PG(LTE4/20:2(11Z,14Z))
PG(LTE4/20:2(11Z,14Z)) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(LTE4/20:2(11Z,14Z)), in particular, consists of one chain of one Leukotriene E4 at the C-1 position and one chain of 11Z,14Z-eicosadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).
(Z)-N-[3-[(2S,8S,11S,14S,17S)-14,17-bis[3-[hydroxy-[(Z)-5-hydroxy-3-methylpent-2-enoyl]amino]propyl]-8,11-bis(hydroxymethyl)-3,6,9,12,15,18-hexaoxo-1,4,7,10,13,16-hexazacyclooctadec-2-yl]propyl]-N,5-dihydroxy-3-methylpent-2-enamide
C41H67N9O17 (957.4654691999999)
(6Z,9Z,12Z,15Z)-N-[(4E,8E)-1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxydodeca-4,8-dien-2-yl]octadeca-6,9,12,15-tetraenamide
C48H79NO18 (957.5296874000001)
(4Z,7Z,10Z,13Z,16Z,19Z)-N-[1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxyoctan-2-yl]docosa-4,7,10,13,16,19-hexaenamide
C48H79NO18 (957.5296874000001)
(7Z,10Z,13Z,16Z,19Z)-N-[(E)-1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxyoct-4-en-2-yl]docosa-7,10,13,16,19-pentaenamide
C48H79NO18 (957.5296874000001)
(7Z,10Z,13Z)-N-[(4E,8E,12E)-1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxytetradeca-4,8,12-trien-2-yl]hexadeca-7,10,13-trienamide
C48H79NO18 (957.5296874000001)
(4Z,7Z,10Z,13Z)-N-[(4E,8E)-1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxytetradeca-4,8-dien-2-yl]hexadeca-4,7,10,13-tetraenamide
C48H79NO18 (957.5296874000001)
(3Z,6Z,9Z,12Z,15Z)-N-[(E)-1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxydodec-4-en-2-yl]octadeca-3,6,9,12,15-pentaenamide
C48H79NO18 (957.5296874000001)
(5Z,8Z,11Z,14Z,17Z)-N-[(E)-1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxydec-4-en-2-yl]icosa-5,8,11,14,17-pentaenamide
C48H79NO18 (957.5296874000001)
(3z)-n-[(1s)-1-{[(1s)-1-{[(2s,3s)-1,3-dihydroxy-4-{[(1s)-1-{[(3s,6s,11r)-8-hydroxy-3-[(4-hydroxyphenyl)methyl]-6-isopropyl-4-methyl-2,5-dioxo-1-oxa-4,7-diazacyclododeca-7,9-dien-11-yl]-c-hydroxycarbonimidoyl}-2-methylpropyl]-c-hydroxycarbonimidoyl}butan-2-yl]-c-hydroxycarbonimidoyl}-2-methylpropyl]-c-hydroxycarbonimidoyl}-2-hydroxyethyl]dec-3-enimidic acid
C48H75N7O13 (957.5422580000001)
(2s,3s)-3-methyl-2-({[(3s,6s,9s,12s,15r)-2,5,11,14-tetrahydroxy-6-[4-(4-hydroxyphenyl)butyl]-3,9-bis[2-(4-hydroxyphenyl)ethyl]-12-isopropyl-7-methyl-8-oxo-1,4,7,10,13-pentaazacyclononadeca-1,4,10,13-tetraen-15-yl]-c-hydroxycarbonimidoyl}amino)pentanoic acid
2-({[5-(aminomethyl)-3,4-dihydroxyoxolan-2-yl]oxy}[3,4-dihydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl)-6-({3-[(4-carboxy-3-methylbutanoyl)oxy]hexadecanoyl}oxy)-1,4-dimethyl-3-oxo-1,4-diazepane-5-carboxylic acid
3-methyl-2-[({2,5,11,14-tetrahydroxy-6-[4-(4-hydroxyphenyl)butyl]-3,9-bis[2-(4-hydroxyphenyl)ethyl]-12-isopropyl-7-methyl-8-oxo-1,4,7,10,13-pentaazacyclononadeca-1,4,10,13-tetraen-15-yl}-c-hydroxycarbonimidoyl)amino]pentanoic acid
(2z)-n-{3-[14,17-bis({3-[(2z)-n,5-dihydroxy-3-methylpent-2-enamido]propyl})-3,6,9,12,15,18-hexahydroxy-5,8-bis(hydroxymethyl)-1,4,7,10,13,16-hexaazacyclooctadeca-1(18),3,6,9,12,15-hexaen-2-yl]propyl}-n,5-dihydroxy-3-methylpent-2-enamide
C41H67N9O17 (957.4654691999999)
(2z)-n-[3-(17-{3-[(2e)-n,5-dihydroxy-3-methylpent-2-enamido]propyl}-14-{3-[(2z)-n,5-dihydroxy-3-methylpent-2-enamido]propyl}-3,6,9,12,15,18-hexahydroxy-5,8-bis(hydroxymethyl)-1,4,7,10,13,16-hexaazacyclooctadeca-1(18),3,6,9,12,15-hexaen-2-yl)propyl]-n,5-dihydroxy-3-methylpent-2-enamide
C41H67N9O17 (957.4654691999999)
(5r,8s,11r,12s,15s,18s,19s,22r)-8-benzyl-15-ethyl-3,6,9,13,16,20-hexahydroxy-18-[(1e,3e,5s,6s)-6-methoxy-3,5-dimethyl-7-phenylhepta-1,3-dien-1-yl]-1,5,12,19-tetramethyl-2-methylidene-25-oxo-1,4,7,10,14,17,21-heptaazacyclopentacosa-3,6,9,13,16,20-hexaene-11,22-dicarboxylic acid
2-{[2-({2-[(1,3-dihydroxy-2-{[hydroxy(6,7,9-trihydroxy-8-{[(7z)-1-hydroxytetradec-7-en-1-ylidene]amino}-3,4,7,8-tetrahydro-2h-1,5-diazonin-2-yl)methylidene]amino}propylidene)amino]-1-hydroxy-5-(n-hydroxyacetamido)pentylidene}amino)-1,3-dihydroxypropylidene]amino}-5-(n-hydroxyacetamido)pentanoic acid
C42H71N9O16 (957.5018525999999)
(2e)-n-[3-(17-{3-[(2e)-n,5-dihydroxy-3-methylpent-2-enamido]propyl}-14-{3-[(2z)-n,5-dihydroxy-3-methylpent-2-enamido]propyl}-3,6,9,12,15,18-hexahydroxy-5,8-bis(hydroxymethyl)-1,4,7,10,13,16-hexaazacyclooctadeca-1(18),3,6,9,12,15-hexaen-2-yl)propyl]-n,5-dihydroxy-3-methylpent-2-enamide
C41H67N9O17 (957.4654691999999)
n-[1-({1-[(1,3-dihydroxy-4-{[1-({8-hydroxy-3-[(4-hydroxyphenyl)methyl]-6-isopropyl-4-methyl-2,5-dioxo-1-oxa-4,7-diazacyclododeca-7,9-dien-11-yl}-c-hydroxycarbonimidoyl)-2-methylpropyl]-c-hydroxycarbonimidoyl}butan-2-yl)-c-hydroxycarbonimidoyl]-2-methylpropyl}-c-hydroxycarbonimidoyl)-2-hydroxyethyl]dec-3-enimidic acid
C48H75N7O13 (957.5422580000001)